Case Study: Patent Reexamination
A key biopharmaceutical manufacturing patent held by an established US biotechnology company was undergoing reexamination proceedings at the US Patent and Trademark Office (USPTO). PharmaVentures supported the law firm representing the established biotechnology company with its in-depth knowledge and expertise.
Drawing upon PharmaVentures' extensive industry experience and insight of intellectual property, Dr Fintan Walton, CEO of PharmaVentures, authored a concise, evidence-based Declaration on primary and secondary considerations of non-obviousness. This led to the USPTO confirming the patentability of all claims of the patent. The decision was final and unappealable.